23andMe's Q3 Topline Beat Estimates On Boost From Telehealth Business Acquisition

23andMe Holding Co (NASDAQ:ME) has updated its FY22 guidance following the inclusion of telehealth operations into its consumer business.

To add Benzinga News as your preferred source on Google, click here.

23andMe Holding Co (NASDAQ:ME) has updated its FY22 guidance following the inclusion of telehealth operations into its consumer business.

The Company closed the acquisition of Lemonaid Health Inc, an on-demand platform for accessing medical care and pharmacy services online, for $400 million.
The Company now expects FY22 sales of $268 - $278 million (consensus of $257.66 million), up from previous guidance of $250 - $260 million.
The projected range for full-year net loss has decreased from $210 - $225 million to $205 - $220 million.
23andMe forecast FY22 adjusted EBITDA loss of $148 to $163 million, compared to the prior guidance of $143 to $158 million.
Related: 23andMe Pivoting To Clinical Research: Could That Lead To A Turnaround For The Stock?
For Q3 FY22, sales increased 2.6% to $56.9 million, beating the consensus of $54.30 million.
Revenues increased primarily due to the addition of two months of Telehealth business revenue from the recent acquisition of Lemonaid Health and higher subscription revenue.
The Company posted EPS of $(0.21), compared to $(0.46) a year ago, missing the consensus of $(0.16).
23andMe ended Q3 with cash of $586 million.
Credit Suisse maintained an Outperform rating on 23andMe and lowered the price target to $11.
Price Action: ME shares closed 7.04% lower at $4.62 during the market session on the last check Friday.

To add Benzinga News as your preferred source on Google, click here.